Parvoduk

RSS
Lapsed

This medicine's authorisation has lapsed

live attenuated Muscovy duck parvovirus
Medicine Veterinary Lapsed
  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Parvoduk has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

български (BG) (279.17 KB - PDF)

View

español (ES) (388.86 KB - PDF)

View

čeština (CS) (432.85 KB - PDF)

View

dansk (DA) (386.36 KB - PDF)

View

Deutsch (DE) (392.74 KB - PDF)

View

eesti keel (ET) (372.5 KB - PDF)

View

ελληνικά (EL) (456.39 KB - PDF)

View

français (FR) (390.28 KB - PDF)

View

hrvatski (HR) (547.54 KB - PDF)

View

italiano (IT) (391.31 KB - PDF)

View

latviešu valoda (LV) (456.12 KB - PDF)

View

lietuvių kalba (LT) (421.48 KB - PDF)

View

magyar (HU) (449.76 KB - PDF)

View

Malti (MT) (440.69 KB - PDF)

View

Nederlands (NL) (388.36 KB - PDF)

View

polski (PL) (432.82 KB - PDF)

View

português (PT) (389.06 KB - PDF)

View

română (RO) (418.94 KB - PDF)

View

slovenčina (SK) (436.71 KB - PDF)

View

slovenščina (SL) (428.53 KB - PDF)

View

Suomi (FI) (387.48 KB - PDF)

View

svenska (SV) (386.11 KB - PDF)

View

Product information

български (BG) (1.19 MB - PDF)

View

español (ES) (804.6 KB - PDF)

View

čeština (CS) (1.03 MB - PDF)

View

dansk (DA) (817.13 KB - PDF)

View

Deutsch (DE) (901.86 KB - PDF)

View

eesti keel (ET) (803.72 KB - PDF)

View

ελληνικά (EL) (1.2 MB - PDF)

View

français (FR) (816.73 KB - PDF)

View

hrvatski (HR) (1.23 MB - PDF)

View

íslenska (IS) (803.26 KB - PDF)

View

italiano (IT) (816.1 KB - PDF)

View

latviešu valoda (LV) (1.05 MB - PDF)

View

lietuvių kalba (LT) (953.35 KB - PDF)

View

magyar (HU) (997.58 KB - PDF)

View

Malti (MT) (1.06 MB - PDF)

View

Nederlands (NL) (808.14 KB - PDF)

View

norsk (NO) (815.13 KB - PDF)

View

polski (PL) (1.17 MB - PDF)

View

português (PT) (803.42 KB - PDF)

View

română (RO) (936.44 KB - PDF)

View

slovenčina (SK) (1.06 MB - PDF)

View

slovenščina (SL) (1.06 MB - PDF)

View

Suomi (FI) (791.59 KB - PDF)

View

svenska (SV) (796.96 KB - PDF)

View
Latest procedure affecting product information:R/0006
09/01/2019

български (BG) (189.97 KB - PDF)

View

español (ES) (281.53 KB - PDF)

View

čeština (CS) (304.72 KB - PDF)

View

dansk (DA) (298.36 KB - PDF)

View

Deutsch (DE) (302.28 KB - PDF)

View

eesti keel (ET) (285.5 KB - PDF)

View

ελληνικά (EL) (325.92 KB - PDF)

View

français (FR) (335.93 KB - PDF)

View

hrvatski (HR) (307.68 KB - PDF)

View

íslenska (IS) (292.58 KB - PDF)

View

italiano (IT) (299.37 KB - PDF)

View

latviešu valoda (LV) (340.5 KB - PDF)

View

lietuvių kalba (LT) (297.31 KB - PDF)

View

magyar (HU) (303.78 KB - PDF)

View

Malti (MT) (306.38 KB - PDF)

View

Nederlands (NL) (313.36 KB - PDF)

View

norsk (NO) (298.06 KB - PDF)

View

polski (PL) (299.63 KB - PDF)

View

português (PT) (297.7 KB - PDF)

View

română (RO) (312.51 KB - PDF)

View

slovenčina (SK) (304.5 KB - PDF)

View

slovenščina (SL) (297.92 KB - PDF)

View

Suomi (FI) (295.81 KB - PDF)

View

svenska (SV) (293.03 KB - PDF)

View

Product details

Name of medicine
Parvoduk
Active substance
live attenuated Muscovy duck parvovirus
International non-proprietary name (INN) or common name
live attenuated Muscovy duck parvovirus
Species
Ducks
Anatomical therapeutic chemical veterinary (ATCvet) code
QI01BD03

Pharmacotherapeutic group

  • duck parvovirus
  • Live viral vaccines
  • Immunologicals for aves

Therapeutic indication

Active immunisation of ducks to prevent mortality1 and to reduce weight loss and lesions of duck parvovirosis and Derzsy's disease.


1In absence of maternally derived antibodies.

Authorisation details

EMA product number
EMEA/V/C/002740
Marketing authorisation holder
Merial

29 Avenue Tony Garnier
69007 Lyon
France

Marketing authorisation issued
11/04/2014
Lapse of marketing authorisation
01/04/2019
Revision
2

Assessment history

This page was last updated on

Share this page